The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | NAPOLI-3: Asian and elderly subgroup analysis of NALIRIFOX in mPAC
Davide Melisi, MD, PhD, University of Verona, Verona, Italy, comments on a post-hoc analysis of the Phase III NAPOLI-3 (NCT04083235) study, evaluating NALIRIFOX versus gemcitabine with nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma (mPAC). In the Asian subgroup, a significant improvement similar to the general cohort in overall survival (OS) and progression-free survival (PFS) with NALIRIFOX was observed. Severe non-hematological events, including diarrhea, were lower compared to the general population. In the 65 years and over cohort, outcomes were also consistent with those of the overall trial population. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
